Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry

Background: Moderate and high efficacy disease modifying therapies (DMTs) have a profound effect on disease activity. The current treatment guidelines only recommend high efficacy DMTs for patients with highly active MS. The objective was to examine the impact of initial treatment choice in achievin...

Cijeli opis

Bibliografski detalji

Glavni autori:	Cecilia Smith Simonsen, Heidi Øyen Flemmen, Line Broch, Cathrine Brunborg, Pål Berg-Hansen, Stine Marit Moen, Elisabeth Gulowsen Celius
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2021-06-01
Serija:	Frontiers in Neurology
Teme:	multiple sclerosis disease modifying therapies no evidence of disease activity disease activity treatment decision
Online pristup:	https://www.frontiersin.org/articles/10.3389/fneur.2021.693017/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!